text: Pulmonary fibrosis secondary to COVID 19 a narrative review b Introduction b Coronavirus disease 2019 COVID 19 is still increasing worldwide and as a result the number of patients with pulmonary fibrosis secondary to COVID 19 will expand over time Risk factors histopathological characterization pathophysiology prevalence and management of post COVID 19 pulmonary fibrosis are poorly understood and few studies have addressed these issues b Areas covered b This article reviews the current evidence regarding post COVID 19 pulmonary fibrosis with an emphasis on the potential risk factors histopathology pathophysiology functional and tomographic features and potential therapeutic modalities A search on the issue was performed in the MEDLINE Embase and SciELO databases and the Cochrane library between 1 December 2019 and 25 January 2021 Studies were reviewed and relevant topics were incorporated into this narrative review b Expert opinion b Pulmonary sequelae may occur secondary to COVID 19 which needs to be included as a potential etiology in the current differential diagnosis of pulmonary fibrosis Therefore serial clinical tomographic and functional screening for pulmonary fibrosis is recommended after COVID 19 mainly in patients with pulmonary involvement in the acute phase of the disease Further studies are necessary to determine the risk factors markers pathophysiology and appropriate management of post COVID 19 pulmonary fibrosis 